Breast Cancer - Data Show Synergistic Activity Of Telomerase Inhibitor Drug And Trast
 

Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, GRN163L, significantly boosts the effects of trastuzumab (Herceptin?) against HER2-positive breast cancer cells and restores sensitivity to trastuzumab in trastuzumab resistant tumor cells. The research published online yesterday in Breast Cancer Research and Treatment was conducted by Dr.

More...